Biolojic Design has announced the launch of a clinical trial of its first-ever computationally designed antibody, AU-007, to treat patients with solid tumours.

A monoclonal antibody, AU-007 uses interleukin-2 (IL-2) of the body to destroy solid cancer tumours.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company transferred the antibody to its spinoff, Aulos Bioscience, which is currently developing it.

Aulos is presently carrying out clinical trials in Australia with patient enrolment underway to report interim results later this year. 

The antibody, which is being developed with $40m proceeds from Series A financing round, will be advanced from the preclinical stage through clinical proof-of-concept by Aulos that was established by Biolojic and life sciences venture capital firm Apple Tree Partners (ATP).

According to preclinical findings, AU-007 showed substantial tumour growth inhibition.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Complete elimination of tumour was observed in ten out of 19 mice treated with the antibody in combination with PD-1 or PD-L1 checkpoint inhibitors in a murine model of cancer.  

Biolojic Design founder and CEO Yanay Ofran said: “Unlike the antibodies made by conventional antibody technologies, the promise of our approach is creating smart antibodies — a sort of nanorobot that, like naturally occurring proteins, is able to adapt to changing situations.

“The antibody that is entering the clinic now was designed based on our understanding of the IL-2 pathway.”

The company leverages its artificial intelligence (AI) platform for designing antibodies with new abilities to treat disease.

Its preclinical portfolio included unique therapies developed using the AI platform.

Currently, Biolojic has collaborations in place with Nektar Therapeutics and Eli Lilly to develop antibodies against autoimmune diseases and diabetes, respectively.